Table 1. Patient characteristics Patient... | American Society of Hematology

Table 1.

Patient characteristics

Patient characteristics	TCD BMT + DLI N = 24	TCD BMT N = 38	All patients N = 62	P
Age (y)
<40	2 (8%)	8 (21%)	10 (16%)	.29
≥40	22 (92%)	30 (79%)	52 (84%)
Donor-patient gender
Female-male	6 (25%)	13 (34%)	19 (31%)	.57
Other	18 (75%)	25 (66%)	43 (69%)
Stage at diagnosis
I-II	11 (46%)	15 (39%)	26 (42%)	.79
III	13 (54%)	23 (61%)	36 (58%)
Type of myeloma
IgA	4 (17%)	15 (11%)	8 (13%)	.70
Other	20 (83%)	34 (89%)	54 (87%)
Time from diagnosis to BMT
<1 year	13 (54%)	12 (32%)	25 (40%)	.11
≥1 year	11 (46%)	26 (68%)	37 (60%)
No. of treatments prior to BMT
1	5 (21%)	3 (8%)	8 (13%)	.24
≥2	19 (79%)	35 (92%)	54 (87%)
Conditioning regimens
CTX/TBI^*	21 (88%)	35 (92%)	56 (92%)
CTX/BU^†	3 (12%)	3 (8%)	6 (9%)

Patient characteristics	TCD BMT + DLI N = 24	TCD BMT N = 38	All patients N = 62	P
Age (y)
<40	2 (8%)	8 (21%)	10 (16%)	.29
≥40	22 (92%)	30 (79%)	52 (84%)
Donor-patient gender
Female-male	6 (25%)	13 (34%)	19 (31%)	.57
Other	18 (75%)	25 (66%)	43 (69%)
Stage at diagnosis
I-II	11 (46%)	15 (39%)	26 (42%)	.79
III	13 (54%)	23 (61%)	36 (58%)
Type of myeloma
IgA	4 (17%)	15 (11%)	8 (13%)	.70
Other	20 (83%)	34 (89%)	54 (87%)
Time from diagnosis to BMT
<1 year	13 (54%)	12 (32%)	25 (40%)	.11
≥1 year	11 (46%)	26 (68%)	37 (60%)
No. of treatments prior to BMT
1	5 (21%)	3 (8%)	8 (13%)	.24
≥2	19 (79%)	35 (92%)	54 (87%)
Conditioning regimens
CTX/TBI^*	21 (88%)	35 (92%)	56 (92%)
CTX/BU^†	3 (12%)	3 (8%)	6 (9%)

TCD indicates T-cell depleted; BMT, bone marrow transplantation; DLI, donor lymphocyte infusion; IgA, immunoglobulin A; TBI, total body irradiation; BU, busulfan.

Cyclophosphamide 60 mg/kg × 2, TBI 1400 cGy.

†

Cyclophosphamide 60 mg/kg × 2, busulfan 16 mg/kg.

View Large

This Feature Is Available To Subscribers Only